c-Myc

Cat. No.

A13725

CAS No.

403811-55-2

10058-F4

10058-F4 is a c-Myc inhibitor that prevents c-Myc/Max dimerization.

Cat. No.

A16324

CAS No.

581073-80-5

KJ Pyr 9

KJ Pyr 9 is a novel small-molecule inhibitor of MYC, KJ-Pyr-9, from a Krhnke pyridine library.

Cat. No.

A17009

CAS No.

1883510-31-3

ML327

ML327 is a blocker of MYC. ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition.

Cat. No.

A17169

CAS No.

413611-93-5

10074-G5

10074-G5 is a c-Myc inhibitor by inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity with IC50 value of 146 μM. 10074-G5 binds to and distorts the bHLH-ZIP domain of c-Myc, thereby inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity. 10074-G5 is capable of binding and sequestering the intrinsically disordered amyloid-β (Aβ) peptide in its monomeric, soluble state. Our analysis reveals that this compound interacts with Aβ and inhibits both the primary and secondary nucleation pathways in its aggregation process.

Cat. No.

A18429

CAS No.

2089-82-9

sAJM589

sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer with an IC50 of 1.8 μM.

Cat. No.

A20130

CAS No.

2223019-53-0

IZCZ-3

IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity.

Cat. No.

A20343

CAS No.

944547-46-0

Mycro 3

Mycro 3 is a potent and selective c-Myc inhibitor in whole cell assays.

Cat. No.

A22431

CAS No.

2289690-31-7

MYCi361

Synonyms: NUCC-0196361; MYCi 361,MYCi-361

MYCi361 (NUCC-0196361) is a MYC inhibitor with the Kd of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy.

Cat. No.

A22432

CAS No.

2289691-01-4

MYCi975

Synonyms: NUCC-0200975; MYCi 975,MYCi-975

MYCi975 (NUCC-0200975) is an orally active MYC inhibitor, which disrupts MYC/MAX interaction, promotes MYC T58 phosphorylation and MYC degradation, and impairs MYC driven gene expression.

Cat. No.

A22700

CAS No.

681282-09-7

MYCMI-6

Synonyms: NSC354961

MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor.

Cat. No.

A30618

CAS No.

256497-58-2

CMLD010509

Synonyms: SDS-1-021

CMLD010509 is a selective inhibitor of c-Myc, targeting the oncogenic translation program associated with multiple myeloma (MM). This compound demonstrates an IC50 of less than 10 nM in various MM cell lines and effectively induces apoptosis. CMLD010509 operates through a phosphorylation-independent mechanism, making it a valuable tool for studying the role of translation in oncogenesis and developing targeted therapeutic strategies in MM research.

Cat. No.

A31254

CAS No.

2636771-45-2

IZTZ-1

IZTZ-1 is an imidazole-benzothiazole conjugate that functions as a c-MYC inhibitor by stabilizing the G-quadruplex (G4) structure of c-MYC. This stabilization results in the downregulation of c-MYC expression, leading to induction of cell cycle arrest and apoptosis in various cell lines, including B16 melanoma cells. Due to its ability to inhibit cell proliferation and exhibit antitumor activity, IZTZ-1 is a valuable tool for researchers studying melanoma and related cancer pathways.

Cat. No.

A32520

CAS No.

828292-11-1

Y502-3888

Y502-3888 is a selective c-Myc inhibitor that targets the G-quadruplex (G4) structure of c-Myc, effectively impairing its transcriptional activity. This compound downregulates c-Myc expression at both mRNA and protein levels, leading to reduced viability and induced apoptosis in myeloma cells. Y502-3888 serves as a valuable tool for investigating the role of c-Myc in multiple myeloma and other related malignancies.

Cat. No.

A32855

CAS No.

3061380-62-6

c-Myc inhibitor 16 iodide

c-Myc inhibitor 16 iodide is a selective inhibitor of the c-Myc G-quadruplex, effectively targeting the c-Myc gene's transcription and translation processes. It disrupts the tumor cell cycle by arresting growth in the G0/G1 phase and activates the mitochondrial apoptosis pathway, leading to early apoptosis in cancer cells. This compound has significant potential in research applications related to breast cancer.

Cat. No.

A32871

CAS No.

2882916-73-4

EP12

EP12 is a selective c-Myc inhibitor that stabilizes c-Myc G-quadruplexes. This compound induces apoptosis and causes DNA damage in multiple myeloma cells, effectively inhibiting their growth. Additionally, EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway, highlighting its potential in cancer research and therapeutic applications.

Cat. No.

A33135

CAS No.

2240186-24-5

(-)-CMLD010509 ((-)-SDS-1-021)

Synonyms: (-)-SDS-1-021

(-)-CMLD010509 is a potent c-Myc inhibitor that selectively targets the oncogenic translation program associated with multiple myeloma. This compound demonstrates significant activity, exhibiting an IC50 of less than 10 nM in various multiple myeloma cell lines, leading to the induction of apoptosis. (-)-CMLD010509 operates through a mechanism that is independent of eIF4E phosphorylation, making it a valuable tool for studying the translation control of key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1.

Cat. No.

A34589

CAS No.

948313-24-4

GW694590A

Synonyms: UNC10112731

GW694590A is an inhibitor targeting firefly luciferase (Fluc) that enhances the stability of the MYC protein, subsequently increasing its endogenous levels. This compound also inhibits receptor tyrosine kinases, demonstrating significant reductions in DDR2, KIT, and PDGFRα activity at 1 μM. GW694590A serves as a versatile protein kinase inhibitor, influencing both ATP-dependent and -independent luciferase systems, making it valuable for studies in cellular signaling and gene expression regulation.

Cat. No.

A39372

CAS No.

1151813-61-4

KSI-3716

KSI-3716 is a potent c-Myc inhibitor that disrupts the binding of c-Myc to MAX, preventing the transcription of target genes. This compound serves as an effective agent in intravesical chemotherapy for bladder cancer, demonstrating significant antitumor activity. Its ability to modulate c-Myc signaling makes it a valuable tool for research into cancer biology and potential therapeutic interventions.

Cat. No.

A53674

CAS No.

57-97-6

DMBA

Synonyms: 7,12-DMBA; 7,12-Dimethylbenzanthracene

DMBA (7,12-Dimethylbenz(a)anthracene) is a potent c-Myc inducer known for its role as a carcinogen due to its polycyclic aromatic hydrocarbon structure. This compound is widely utilized in experimental research to induce tumor formation in rodent models, enabling the study of cancer biology, tumorigenesis, and potential therapeutic interventions. Its application is critical in understanding the mechanisms of cancer development and the role of oncogenes.

Cat. No.

A53675

CAS No.

2095780-08-6

WBC100

Synonyms: 14-D-Valine-TPL

WBC100 is a selective c-Myc inhibitor that functions as a molecular glue degrader targeting the ubiquitin E3 ligase CHIP to promote degradation via the 26S proteasome pathway. This compound demonstrates potent activity in models of c-Myc overexpressing tumors, enabling researchers to study its effects on tumor growth and progression. WBC100 is a valuable tool for investigating the role of c-Myc in various cancer types and for exploring potential therapeutic strategies.

Cat. No.

A53683

CAS No.

667909-97-9

MY05

MY05 is a selective inhibitor of the c-MYC protein, effectively disrupting the MYC-MAX interaction. This compound engages intracellular c-MYC, modulating its thermal stability and leading to a reduction in c-MYC transcriptional targets. MY05 demonstrates significant anticancer activity, particularly in triple-negative breast cancer (TNBC), making it a valuable tool for research in cancer biology and therapeutics.

Cat. No.

A53684

CAS No.

2768765-58-6

c-Myc inhibitor 6

c-Myc inhibitor 6 is a selective c-Myc inhibitor that effectively reduces cancer cell viability while promoting the degradation of the c-Myc protein. This compound is invaluable for research into c-Myc dysregulation, which is implicated in various pathologies, including cancer, cardiovascular diseases, and viral infections. Its ability to target c-Myc positions it as a potential therapeutic agent in studies aimed at understanding and treating these conditions.

Cat. No.

A53685

CAS No.

3042878-82-7

MYC-IN-3

MYC-IN-3 is a potent MYC inhibitor that demonstrates significant antiproliferative activity. This compound exhibits strong anticancer effects and is particularly relevant for research focused on prostate cancer models. Its unique mechanism targeting MYC makes it a valuable tool for investigating MYC-driven malignancies and therapeutic strategies.

Cat. No.

A53686

CAS No.

1942834-87-8

c-Myc ligand 1

c-Myc ligand 1 is a potent c-Myc inhibitor that functions as a target protein ligand for PROTAC (Proteolysis Targeting Chimera) technology. This compound is essential for the synthesis of the PROTAC c-Myc inhibitor 7, facilitating studies in cellular regulation and tumorigenesis. It serves as a critical tool in research focused on targeting and degrading oncogenic proteins associated with various cancers.

Cat. No.

A53687

CAS No.

342416-30-2

IRES-C11

IRES-C11 is an inhibitor of the c-MYC internal ribosome entry site (IRES) that specifically disrupts the interaction between the c-MYC IRES and its essential trans-acting factor, heterogeneous nuclear ribonucleoprotein A1. This selective inhibition allows for targeted modulation of c-MYC translation without affecting other IRES-mediated translations, such as those involving BAG-1, XIAP, and p53. IRES-C11 is a valuable tool for research investigating the regulatory mechanisms of c-MYC translation and its implications in cancer biology.